Aardvark Therapeutics, Inc. (AARD) income statement
AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.91−0.24 (-20.87%)
Close on Nov 18, 2026Market cap $19.92MP/E –Yield –
Aardvark Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -221.5%
Financial strength
- Current ratio
- 12.63
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 1156.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.27
- Dividend yield
- –
See a number that looks wrong?